Preclinical research in Rett syndrome: Setting the foundation for translational success

David M. Katz, Joanne E. Berger-Sweeney, James H. Eubanks, Monica J. Justice, Jeffrey L. Neul, Lucas Pozzo-Miller, Mary E. Blue, Diana Christian, Jacqueline Crawley, Maurizio Giustetto, Jacky Guy, C. James Howell, Miriam Kron, Sacha B. Nelson, Rodney C. Samaco, Laura R. Schaevitz, Coryse St Hillaire-Clarke, Juan L. Young, Huda Y. Zoghbi, Laura A. Mamounas

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

In September of 2011, the National Institute of Neurological Disorders and Stroke (NINDS), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the International Rett Syndrome Foundation (IRSF) and the Rett Syndrome Research Trust (RSRT) convened a workshop involving a broad cross-section of basic scientists, clinicians and representatives from the National Institutes of Health (NIH), the US Food and Drug Administration (FDA), the pharmaceutical industry and private foundations to assess the state of the art in animal studies of Rett syndrome (RTT). The aim of the workshop was to identify crucial knowledge gaps and to suggest scientific priorities and best practices for the use of animal models in preclinical evaluation of potential new RTT therapeutics. This review summarizes outcomes from the workshop and extensive follow-up discussions among participants, and includes: (1) a comprehensive summary of the physiological and behavioral phenotypes of RTT mouse models to date, and areas in which further phenotypic analyses are required to enhance the utility of these models for translational studies; (2) discussion of the impact of genetic differences among mouse models, and methodological differences among laboratories, on the expression and analysis, respectively, of phenotypic traits; and (3) definitions of the standards that the community of RTT researchers can implement for rigorous preclinical study design and transparent reporting to ensure that decisions to initiate costly clinical trials are grounded in reliable preclinical data.

Original languageEnglish (US)
Pages (from-to)733-745
Number of pages13
JournalDMM Disease Models and Mechanisms
Volume5
Issue number6
DOIs
StatePublished - Nov 2012

Fingerprint

Rett Syndrome
Research
Animals
Health
Education
National Institute of Child Health and Human Development (U.S.)
National Institute of Neurological Disorders and Stroke
National Institutes of Health (U.S.)
Drug Industry
United States Food and Drug Administration
Practice Guidelines
Animal Models
Research Personnel
Clinical Trials
Pharmaceutical Preparations
Phenotype
Industry

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine (miscellaneous)
  • Immunology and Microbiology (miscellaneous)
  • Neuroscience (miscellaneous)

Cite this

Katz, D. M., Berger-Sweeney, J. E., Eubanks, J. H., Justice, M. J., Neul, J. L., Pozzo-Miller, L., ... Mamounas, L. A. (2012). Preclinical research in Rett syndrome: Setting the foundation for translational success. DMM Disease Models and Mechanisms, 5(6), 733-745. https://doi.org/10.1242/dmm.011007

Preclinical research in Rett syndrome : Setting the foundation for translational success. / Katz, David M.; Berger-Sweeney, Joanne E.; Eubanks, James H.; Justice, Monica J.; Neul, Jeffrey L.; Pozzo-Miller, Lucas; Blue, Mary E.; Christian, Diana; Crawley, Jacqueline; Giustetto, Maurizio; Guy, Jacky; Howell, C. James; Kron, Miriam; Nelson, Sacha B.; Samaco, Rodney C.; Schaevitz, Laura R.; Hillaire-Clarke, Coryse St; Young, Juan L.; Zoghbi, Huda Y.; Mamounas, Laura A.

In: DMM Disease Models and Mechanisms, Vol. 5, No. 6, 11.2012, p. 733-745.

Research output: Contribution to journalArticle

Katz, DM, Berger-Sweeney, JE, Eubanks, JH, Justice, MJ, Neul, JL, Pozzo-Miller, L, Blue, ME, Christian, D, Crawley, J, Giustetto, M, Guy, J, Howell, CJ, Kron, M, Nelson, SB, Samaco, RC, Schaevitz, LR, Hillaire-Clarke, CS, Young, JL, Zoghbi, HY & Mamounas, LA 2012, 'Preclinical research in Rett syndrome: Setting the foundation for translational success', DMM Disease Models and Mechanisms, vol. 5, no. 6, pp. 733-745. https://doi.org/10.1242/dmm.011007
Katz DM, Berger-Sweeney JE, Eubanks JH, Justice MJ, Neul JL, Pozzo-Miller L et al. Preclinical research in Rett syndrome: Setting the foundation for translational success. DMM Disease Models and Mechanisms. 2012 Nov;5(6):733-745. https://doi.org/10.1242/dmm.011007
Katz, David M. ; Berger-Sweeney, Joanne E. ; Eubanks, James H. ; Justice, Monica J. ; Neul, Jeffrey L. ; Pozzo-Miller, Lucas ; Blue, Mary E. ; Christian, Diana ; Crawley, Jacqueline ; Giustetto, Maurizio ; Guy, Jacky ; Howell, C. James ; Kron, Miriam ; Nelson, Sacha B. ; Samaco, Rodney C. ; Schaevitz, Laura R. ; Hillaire-Clarke, Coryse St ; Young, Juan L. ; Zoghbi, Huda Y. ; Mamounas, Laura A. / Preclinical research in Rett syndrome : Setting the foundation for translational success. In: DMM Disease Models and Mechanisms. 2012 ; Vol. 5, No. 6. pp. 733-745.
@article{5b10eafc36ae468294c7e71c0bf210a3,
title = "Preclinical research in Rett syndrome: Setting the foundation for translational success",
abstract = "In September of 2011, the National Institute of Neurological Disorders and Stroke (NINDS), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the International Rett Syndrome Foundation (IRSF) and the Rett Syndrome Research Trust (RSRT) convened a workshop involving a broad cross-section of basic scientists, clinicians and representatives from the National Institutes of Health (NIH), the US Food and Drug Administration (FDA), the pharmaceutical industry and private foundations to assess the state of the art in animal studies of Rett syndrome (RTT). The aim of the workshop was to identify crucial knowledge gaps and to suggest scientific priorities and best practices for the use of animal models in preclinical evaluation of potential new RTT therapeutics. This review summarizes outcomes from the workshop and extensive follow-up discussions among participants, and includes: (1) a comprehensive summary of the physiological and behavioral phenotypes of RTT mouse models to date, and areas in which further phenotypic analyses are required to enhance the utility of these models for translational studies; (2) discussion of the impact of genetic differences among mouse models, and methodological differences among laboratories, on the expression and analysis, respectively, of phenotypic traits; and (3) definitions of the standards that the community of RTT researchers can implement for rigorous preclinical study design and transparent reporting to ensure that decisions to initiate costly clinical trials are grounded in reliable preclinical data.",
author = "Katz, {David M.} and Berger-Sweeney, {Joanne E.} and Eubanks, {James H.} and Justice, {Monica J.} and Neul, {Jeffrey L.} and Lucas Pozzo-Miller and Blue, {Mary E.} and Diana Christian and Jacqueline Crawley and Maurizio Giustetto and Jacky Guy and Howell, {C. James} and Miriam Kron and Nelson, {Sacha B.} and Samaco, {Rodney C.} and Schaevitz, {Laura R.} and Hillaire-Clarke, {Coryse St} and Young, {Juan L.} and Zoghbi, {Huda Y.} and Mamounas, {Laura A.}",
year = "2012",
month = "11",
doi = "10.1242/dmm.011007",
language = "English (US)",
volume = "5",
pages = "733--745",
journal = "DMM Disease Models and Mechanisms",
issn = "1754-8403",
publisher = "Company of Biologists Ltd",
number = "6",

}

TY - JOUR

T1 - Preclinical research in Rett syndrome

T2 - Setting the foundation for translational success

AU - Katz, David M.

AU - Berger-Sweeney, Joanne E.

AU - Eubanks, James H.

AU - Justice, Monica J.

AU - Neul, Jeffrey L.

AU - Pozzo-Miller, Lucas

AU - Blue, Mary E.

AU - Christian, Diana

AU - Crawley, Jacqueline

AU - Giustetto, Maurizio

AU - Guy, Jacky

AU - Howell, C. James

AU - Kron, Miriam

AU - Nelson, Sacha B.

AU - Samaco, Rodney C.

AU - Schaevitz, Laura R.

AU - Hillaire-Clarke, Coryse St

AU - Young, Juan L.

AU - Zoghbi, Huda Y.

AU - Mamounas, Laura A.

PY - 2012/11

Y1 - 2012/11

N2 - In September of 2011, the National Institute of Neurological Disorders and Stroke (NINDS), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the International Rett Syndrome Foundation (IRSF) and the Rett Syndrome Research Trust (RSRT) convened a workshop involving a broad cross-section of basic scientists, clinicians and representatives from the National Institutes of Health (NIH), the US Food and Drug Administration (FDA), the pharmaceutical industry and private foundations to assess the state of the art in animal studies of Rett syndrome (RTT). The aim of the workshop was to identify crucial knowledge gaps and to suggest scientific priorities and best practices for the use of animal models in preclinical evaluation of potential new RTT therapeutics. This review summarizes outcomes from the workshop and extensive follow-up discussions among participants, and includes: (1) a comprehensive summary of the physiological and behavioral phenotypes of RTT mouse models to date, and areas in which further phenotypic analyses are required to enhance the utility of these models for translational studies; (2) discussion of the impact of genetic differences among mouse models, and methodological differences among laboratories, on the expression and analysis, respectively, of phenotypic traits; and (3) definitions of the standards that the community of RTT researchers can implement for rigorous preclinical study design and transparent reporting to ensure that decisions to initiate costly clinical trials are grounded in reliable preclinical data.

AB - In September of 2011, the National Institute of Neurological Disorders and Stroke (NINDS), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the International Rett Syndrome Foundation (IRSF) and the Rett Syndrome Research Trust (RSRT) convened a workshop involving a broad cross-section of basic scientists, clinicians and representatives from the National Institutes of Health (NIH), the US Food and Drug Administration (FDA), the pharmaceutical industry and private foundations to assess the state of the art in animal studies of Rett syndrome (RTT). The aim of the workshop was to identify crucial knowledge gaps and to suggest scientific priorities and best practices for the use of animal models in preclinical evaluation of potential new RTT therapeutics. This review summarizes outcomes from the workshop and extensive follow-up discussions among participants, and includes: (1) a comprehensive summary of the physiological and behavioral phenotypes of RTT mouse models to date, and areas in which further phenotypic analyses are required to enhance the utility of these models for translational studies; (2) discussion of the impact of genetic differences among mouse models, and methodological differences among laboratories, on the expression and analysis, respectively, of phenotypic traits; and (3) definitions of the standards that the community of RTT researchers can implement for rigorous preclinical study design and transparent reporting to ensure that decisions to initiate costly clinical trials are grounded in reliable preclinical data.

UR - http://www.scopus.com/inward/record.url?scp=84870018625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870018625&partnerID=8YFLogxK

U2 - 10.1242/dmm.011007

DO - 10.1242/dmm.011007

M3 - Article

C2 - 23115203

AN - SCOPUS:84870018625

VL - 5

SP - 733

EP - 745

JO - DMM Disease Models and Mechanisms

JF - DMM Disease Models and Mechanisms

SN - 1754-8403

IS - 6

ER -